The abovementioned considerations suggest that the potential new mechanism by which lorcaserin reduced depression-like behavior during nicotine withdrawal may be that reduced 5-HT levels in the hippocampus are replaced by the 5-HT2C receptor agonist lorcaserin. Here, HTR5A is linked to depressive symptom measurement.